Meibomian Gland

The combination of intense pulsed light and meibomian gland expression could be “safe and useful” for improving signs of dry eye disease in those with moderate to severe symptoms, according to a study in PLoS ONE.

A study confirmed the efficacy of intense pulsed light treatment combined with meibomian gland expression vs. monotherapy meibomian gland expression in patients with moderate to severe dry eye disease due to meibomian gland dysfunction.

CHICAGO – Treatment with Alcon’s Systane iLux for meibomian gland dysfunction resulted in improvement in clinical findings at 2 weeks and 12 months, Shane Kannarr, OD, said at Optometry’s Meeting.

WASHINGTON — Patients with dry eye disease treated with NOV03 eye drops experienced improvements in both signs and symptoms, according to a study.

The Systane iLux2 meibomian gland dysfunction thermal pulsation system delivers heat and pressure therapy while allowing patients to visualize their treatment, according to an Alcon press release.

Topical glaucoma medication may alter the structure and function of patients’ meibomian glands, particularly if preservative is present in the drop, according to data published in Optometry and Vision Science.

The TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction, according to a press release from Sight Sciences.

With the exception of the eventual, however begrudging, acceptance of dry eye disease as a thing, the biggest paradigm shift in the dry eye world has been the acknowledgement that both tear quality and quantity matter.

Treating patients with TearScience LipiFlow prior to cataract surgery resulted in a reduction of halos and an improvement in meibomian gland score, according to a study sponsored by Johnson & Johnson Vision.

Patients reported major improvements to their dry eye disease symptoms and better functioning meibomian glands after receiving treatment with the TearCare system, according to a study published in Optometry and Vision Science.